Pharma margins are under pressure — here's what cost accounting does about it

Pharmaceutical businesses operate in one of the most margin-compressed environments I work in. You have regulatory compliance costs that are non-negotiable. You have medical-aid pricing structures that cap what you can charge on certain product lines. You have supply chains that run across borders, making every fuel and logistics price movement a direct hit to your cost base. And you're expected to maintain quality that leaves no room for shortcuts.

When a pharma business comes to me and says margins have dropped 4 percentage points in 18 months, I'm not surprised. I'm also not helpless. There are specific places cost accounting looks that standard management accounts don't. Here's the process.

Start with a product-level profitability rebuild

Most pharma businesses I encounter have total-company margin visibility but limited product-level margin visibility. They know the business made 14% gross margin last year. They don't know which product lines made 22% and which made 6%.

This matters because the strategic response to margin pressure differs completely depending on where the pressure is coming from. If the squeeze is on your highest-volume commodity lines, that's a different problem than if it's on your specialist products — and the fix looks nothing alike.

Step one is always the same: build a contribution analysis by product line. Revenue, direct materials, direct labour, direct overhead — down to contribution margin per SKU. This usually takes two to three weeks of analysis. What comes out of it consistently surprises people.

Isolate the regulatory cost layer

Regulatory compliance in pharma is a real cost centre that often gets buried in general overhead. Registration fees, batch release testing, stability studies, quality assurance staff time — these costs exist and they need to be allocated accurately to the product lines that generate them.

When regulatory costs are pooled into general overhead and spread evenly across the range, low-regulation products subsidise high-regulation products. You end up making strategic decisions — keep this product line, discontinue that one — based on margins that are structurally misstated.

Activity-based costing, even a simplified version of it, fixes this. Allocate regulatory costs to the products that actually require them. Now your margin picture reflects reality.

The logistics cost problem

Cold chain, specialised packaging, cross-border freight — pharma logistics costs are not trivial and they've moved materially. If your standard cost cards for imported raw materials were set before the last major rand weakness or fuel cycle, you're understating COGS on every product that uses those inputs.

The discipline here is regular standard cost reviews — quarterly at minimum for businesses with significant import exposure. Not the full rebuild every quarter, but a targeted update of the input costs that have moved more than 5%. It's 20% of the effort and catches 80% of the error.

Medical-aid pricing: know which lines are price-capped

For businesses selling into the medical-aid reimbursement channel, certain product lines have effectively capped prices regardless of what your cost base does. These are the lines where cost control is the only margin lever — you cannot price your way to profitability.

The strategic response is to know which lines are price-capped and manage them as a portfolio. Accept lower margins on price-constrained lines if they drive volume that supports your higher-margin specialist products. Or, if the capped lines are genuinely underwater, make the discontinuation decision deliberately rather than by default.

The three-month diagnostic

When I take on a pharma engagement, the first three months follow a consistent structure:

1. Month 1: Product-level contribution analysis — where is the margin actually coming from?
2. Month 2: Cost driver analysis — logistics, regulatory, labour absorption, overhead allocation. Where are the standard costs wrong?
3. Month 3: Actionable margin recovery plan — specific product, pricing, and cost decisions with projected margin impact quantified.

In a R30M revenue pharma business, this process typically identifies R1.5M to R3M of annual margin improvement opportunity. Not all of it is recoverable — some costs are genuinely fixed and the only lever is volume. But a meaningful portion of it is recoverable within 6 to 12 months through decisions the business has the authority to make.

If margins are moving in the wrong direction and you're not sure exactly why, that's the work. Take a seat in the boardroom and tell me about your product range. We'll start with a conversation, not a proposal.